Patient characteristics | Univariate Analysis | Multivariate Analysis | |||||
---|---|---|---|---|---|---|---|
OR | 95% CI | P | OR | 95% CI | P | ||
Gender | Â | Â | Â | Â | Â | Â | |
 | Female | ref |  |  |  |  |  |
 | Male | 3.609 | 0.813–16.022 | 0.091 | 2.199 | 0.438–11.049 | 0.339 |
Age | Â | Â | Â | Â | Â | Â | |
 | <60 years | ref |  |  |  |  |  |
 | ≥ 60 years | 1.744 | 0.71–4.284 | 0.225 |  |  |  |
BMI | Â | Â | Â | Â | Â | Â | |
 | <25 kg/m2 | ref |  |  |  |  |  |
 | ≥ 25 kg/m2 | 1.966 | 0.71–5.445 | 0.194 |  |  |  |
Tumor location | Â | Â | 0.988 | Â | Â | Â | |
 | Upper stomach | ref |  |  |  |  |  |
 | Middle stomach | 0.916 | 0.281–2.988 | 0.844 |  |  |  |
 | Lower stomach | 0.945 | 0.344–2.593 | 0.913 |  |  |  |
Tumor size | Â | Â | Â | Â | Â | Â | |
 | <5.8 cm | ref |  |  |  |  |  |
 | ≥5.8 cm | 0.824 | 0.339–2.004 | 0.67 |  |  |  |
Pre-treatment NLR | Â | Â | Â | Â | Â | Â | |
 | <2.86 | ref |  |  |  |  |  |
 | ≥ 2.86 | 0.355 | 0.133–0.948 | 0.039 | 0.193 | 0.016–0.611 | 0.005 |
Pre-treatment PLR | Â | Â | Â | Â | Â | Â | |
 | <182 | ref |  |  |  |  |  |
 | ≥ 182 | 0.137 | 0.039–0.478 | 0.002 | 0.077 | 0.018–0.333 | 0.001 |
CEA | Â | Â | Â | Â | Â | Â | |
 | <5.2ng/ml | ref |  |  |  |  |  |
 | ≥ 5.2ng/ml | 1.628 | 0.657–4.035 | 0.292 |  |  |  |
CA19-9 | Â | Â | Â | Â | Â | Â | |
 | <27U/ml | ref |  |  |  |  |  |
 | ≥ 27U/ml | 0.624 | 0.219–1.773 | 0.376 |  |  |  |
Degree of differentiation | Â | Â | Â | Â | Â | Â | |
 | poor/mucinous | ref |  |  |  |  |  |
 | moderate/well | 0.994 | 0.409–2.417 | 0.989 |  |  |  |
HER-2 | Â | Â | Â | Â | Â | Â | Â |
 | negative | ref |  |  |  |  |  |
 | positive | 2.756 | 0.352–21.561 | 0.334 |  |  |  |
Clinical T stage | Â | Â | 0.907 | Â | Â | Â | |
 | T3 | ref |  |  |  |  |  |
 | T4a | 0.854 | 0.309–2.357 | 0.76 |  |  |  |
 | T4b | 1.154 | 0.208–6.413 | 0.87 |  |  |  |
Clinical N stage | Â | Â | 0.062 | Â | Â | 0.064 | |
 | N0 | ref |  |  | ref |  |  |
 | N1 | 0.208 | 0.048–0.905 | 0.036 | 0.445 | 0.069–2.875 | 0.395 |
 | N2 | 0.317 | 0.097–1.039 | 0.058 | 1.044 | 0.063–17.217 | 0.976 |
 | N3 | 0.88 | 0.248–3.128 | 0.843 | 5.391 | 0.303–95.933 | 0.251 |
Clinical TNM stage | Â | Â | Â | Â | Â | Â | |
 | II | ref |  |  |  |  |  |
 | III | 0.42 | 0.163–1.078 | 0.071 | 0.306 | 0.025–3.74 | 0.354 |
Chemotherapy regimen | Â | Â | Â | Â | Â | Â | |
 | DOS | ref |  |  |  |  |  |
 | NPOS | 1.156 | 0.461–2.896 | 0.757 |  |  |  |
Arterial chemoembolization | Â | Â | Â | Â | Â | Â | |
 | No | ref |  |  |  |  |  |
 | Yes | 3.84 | 1.359–10.853 | 0.011 | 3.766 | 1.177–12.054 | 0.025 |
Number of chemotherapy cycles | Â | Â | 0.531 | Â | Â | Â | |
 | 2 | ref |  |  |  |  |  |
 | 3 | 0.541 | 0.186–1.579 | 0.261 |  |  |  |
 | 4 | 0.806 | 0.215–3.024 | 0.749 |  |  |  |